---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-036860"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:56:46.718190+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health reports 2022 prescription revenue up 179% to $11.9M; net loss narrows to $48.4M

## Summary
- Prescription product net revenue $11.9M for 2022, up 179% YoY from $4.3M in 2021.
- Net loss attributable to common shareholders $47.5M ($36.18 per share) vs $52.6M in 2021.
- Cash position approximately $15.3M as of March 24, 2023.
- Phase 3 OnTarget trial enrollment at ~80%; completion expected in Q2 2023.
- Orphan Drug Designation granted for crofelemer for MVID; IND submission planned Q2 2023.

## SEC filing metadata
- accession: 0001104659-23-036860
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/0001104659-23-036860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/tm2310147d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-036860
- JSON: https://secwatch.observer/filing/0001104659-23-036860.json
- Plain text: https://secwatch.observer/filing/0001104659-23-036860.txt

## Key facts
- Earnings Releases
  Jaguar Health, Inc. reported the year ended December 31, 2022 results: revenue approximately $11.9 million.
  - Period: the year ended December 31, 2022
  - Revenue: approximately $11.9 million
  - Result: reported results
  source text: Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000110465923036860/0001104659-23-036860-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.